Page last updated: 2024-11-01

nitidine and Leukemia, Myelogenous, Chronic, BCR-ABL Positive

nitidine has been researched along with Leukemia, Myelogenous, Chronic, BCR-ABL Positive in 1 studies

nitidine: RN given refers to parent cpd; synonym NSC 146397 refers to chloride; structure

Leukemia, Myelogenous, Chronic, BCR-ABL Positive: Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Liu, N1
Li, P1
Zang, S1
Liu, Q1
Ma, D1
Sun, X1
Ji, C1

Other Studies

1 other study available for nitidine and Leukemia, Myelogenous, Chronic, BCR-ABL Positive

ArticleYear
Novel agent nitidine chloride induces erythroid differentiation and apoptosis in CML cells through c-Myc-miRNAs axis.
    PloS one, 2015, Volume: 10, Issue:2

    Topics: Antineoplastic Agents; Apoptosis; Benzophenanthridines; Cell Differentiation; Down-Regulation; Drug

2015